AIDS Healthcare Foundation appeals against court decision in Gilead case

12 July 2016

The non-profit, USA-based, AIDS Healthcare Foundation (AHF) will appeal the dismissal of its federal lawsuit against US biotech major Gilead Sciences (Nasdaq: GILD) and other defendants alleging drug patent manipulation and anti-trust claims relating to slightly different formulations of the HIV drug tenofovir.

Although the US District Court for the Northern District of California last week granted a motion to dismiss sought by Gilead, the judge nonetheless suggested that this case was ripe for reconsideration by a higher court.

The AHF believes its stance can clear the way for generic and biosimilars manufacturers to bring down prices for patients, even when pharma companies are seeking to extend patents.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK